Delivery Order SPE2DB25D3306-SPE2DB25FUCMZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $3,544.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $44,409.63 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on July 30, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents a single transaction with a completion date of July 31, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.56 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $35,946.82 to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside transaction and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $2,348.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 5 mg/0.5 ml pen injections, with performance completion targeted for August 4, 2025. The contract, awarded August 1, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCMZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,590.18 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded pharmaceutical supply transaction supporting federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The underlying IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems worldwide. Zepbound (tirzepatide), a diabetes and weight management medication, aligns with the contractor's extensive portfolio of specialty pharmaceutical products supporting Defense Health Agency and other federal healthcare entities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 8/5/25 |